Skip to main content

Biomarkers

Biomarkers

CRP

Serum CRP is useful for assessing a patient’s risk of relapse. High levels are indicative of active disease or a bacterial complication. 

ECCO statement 4C (CD 2016)

Serum CRP levels and faecal markers, such calprotectin or lactoferrin can be used to guide therapy and short-term follow-up [EL2] and to predict clinical relapse [EL2]. Faecal calprotectin can help to differentiate CD from IBS [EL2]

ESR

Less than 10% of patients do not significantly augment serum CRP in response to inflammation. ESR measurements can be useful in such patients, and particularly in paediatric cases, to serologically test for inflammation.

Faecal biomarkers

Faecal biomarkers reflect the migration of neutrophils through the inflamed bowel wall to the mucosa (with subsequent shedding into the gut lumen).  Calprotectin and lactoferrin are stable, degradation-resistant proteins that can be easily measured in faeces. They reflect intestinal inflammation of any cause, and in known Crohn’s disease have > 90% positive predictive value for endoscopically active disease. They are superior to CRP, and clearly superior to the CDAI, for predicting active disease in those suspected of having Crohn’s with a sensitivity of 60-70%; with lower sensitivities in those with lone ileal disease.

ECCO statement 4C (CD 2016)

Serum CRP levels and faecal markers, such calprotectin or lactoferrin can be used to guide therapy and short-term follow-up [EL2] and to predict clinical relapse [EL2]. Faecal calprotectin can help to differentiate CD from IBS [EL2]

Genetic markers

Although more than 160 genetic loci associated with IBD have been discovered, no loci or collection of loci are sensitive or specific enough to diagnose these conditions.